Serumska IgG antitela protiv Helicobacter pylori antigena male molekulske mase 50kDa, 30kDa i ureaza A 26kDa, uporedo sa vakuolizirajućim citotoksinom A povezana su sa ishodom infekcije
Sažetak
Uvod/Cilj. Do sada objavljene studije o seroreaktivnosti protiv Helicobacter pylori antigena male molekulske mase kao i citotoksina povezanog sa genom A (CagA), vakuolizirajućeg citoksina (VacA) kod bolesnika sa karcinomom želuca i peptičkim ulkusom pokazale su protivurečne rezultate, te smo u cilju istraživanja ove pojave dizajnirali i sproveli ovu studiju. Metode. Western blot test primenjen je kod 123 ispitanika, 31 sa karcinomom želuca, 31 sa ulkusom duodenuma, 31 sa ulkusom želuca, 30 sa gastritisom i funkcionalnom dispepsijom u cilju određivanja IgG antitela protiv H. pylori antigena (CagA, VacA, Heat shock protein 60kDa, Urease B66kDa, Flagelin55 kDa, 50kDa, 30 kDa, Urease A26 kDa, 24 kDa). U ovoj studiji analizirali smo: razlike u seroreaktivnosti na H. pylori antigene između grupe sa funkcionalnom dispepsijom i ostalih grupa; između gradusa različitih patohistoloških parametara inflamacije antralne i korpusne mukoze i između antrum predominantnog gastritisa i korpus predominantnog pangastritisa. Rezultati. Seropozitivnost protiv 50 kDa antigena pokazala se kao biomarker za funkcionalnu dispepsiju, seropozitivnost protiv 30 kDa antigena bila je biomarker za antrum predominantni gastritis i gradus kolonizacije H. pylori u antrumu, protiv Urease A26 kDa antigena za pangastritis i korpus predominantni gastritis i stepen inflamacije u korpusu. Seropozitivnost protiv VacA bila je biomarker za karcinom želuca i peptički ulkus, kada se razmatraju kao jedinstvena grupa, i za inflamaciju antralne mukoze. Seropozitivnost protiv CagA bila je povezana sa intenzivnijom inflamacijom antralne i korpusne mukoze, Urease B66kDa antigena sa inflamacijom korpusne mukoze, ali ne i sa specifičnim ishodom H. pylori infekcije i topografskom distribucijom inflamacije želuca. Zaključak. Serumska IgG antitela protiv H. pylori antigena 50 kDa i VacA mogu predstavljati korisne biomarkere za specifični ishod H. pylori infekcije, dok bi antitela protiv 30 kDa i Urease A26 kDa antigena mogla biti specifični biomarkeri za različitu topografsku distrubuciju inflamacije želudačne mukoze.
Reference
Hooi KY, Lai YW, Khoon Ng W, Suen MY, Underwood EF, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastro¬en-terology 2017; 153(2): 420–9.
Chmiela M, Karwowska Z, Gonciarz W, Allushi B, Stączek P. Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol 2017; 23(9): 1521–40.
Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134(1): 306–23.
Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2: 59–69.
Cello JP. Helicobacter pylori and peptic ulcer disease. AJR Am J Roentgenol 1995; 164(2): 283–6.
Talley NJ, Quan C. Review article: Helicobacter pylori and nonulcer dyspepsia. Aliment Pharmacol Ther 2002; 16 Suppl 1: 58–65.
Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and How to Test for Helicobacter pylori Infection. Gastroenterol Res Pract 2016; 2016: 8463614.
Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis Biomed J 2016; 39(1): 14–23.
Li Q, Liu J, Gong Y, Yuan Y. Serum VacA antibody is associated with risks of peptic ulcer and gastric cancer: A meta-analysis. Microb Pathog 2016; 99: 220–8.
Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 2014; 15(3): 306–16.
Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015; 7(12): 455–65.
Zhao Z, Li Y, Liu S, Fu W. Serum Helicobacter pylori CagA antibody may not be used as a tumor marker for diagnosing gastric cancer in east Asian countries. Tumour Biol 2014; 35(12): 12217–24.
Shiesh SC, Sheu BS, Yang HB, Tsao HJ, Lin XZ. Serologic response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan. Dig Dis Sci 2000; 45(4): 781–8.
Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996; 91(9): 1785–8.
Lamarque D, Gilbert T, Roudaut-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11(7): 721–6.
Kuo CH, Wu DC, Lu CY, Su YC, Yu FJ, Lee YC, et al. Low molecular weight protein of Helicobacter pylori and its relation to gastroduodenal diseases. Hepatogastroenterol 2003; 50(52): 897–901.
Karami N, Talebkhan Y, Saberi S, Esmaeili M, Oghalaie A, Abdirad A, et al. Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancer. Asian Pac J Cancer Prev 2013; 14(3): 1813–7.
Chomvarin C, Ottiwet O, Hahnvajanawong C, Intapan PM, Wongwajana S. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases. Int J Infect Dis 2009; 13(5): 647–54.
Vilaichone RK, Mahachai V, Kositchaiwat C, Graham DY, Yamaoka Y. Relation between seroreactivity to low-molecular-weight Helicobacter pylori-specific antigens and disease presentation. Clin Diagn Lab Immunol 2003; 10(6): 1025–8.
Filipec Kanizaj T, Katicić M, Presecki V, Gasparov S, Colić Cvrlje V, Kolarić B, et al. Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases-cross-sectional study. Croat Med J 2009; 50(2): 124–32.
Yang KC, Chu A, Liao CS, Lin YM, Wang GM. Evaluation of the role of H. pylori infection in pathogenesis of gastric cancer by immunoblot assay. World J Gastroenterol 2006; 12(43): 7029–32.
Schumann C, Triantafilou K, Rasche FM, Möricke A, Vogt K, Triantafilou M, et al. Serum antibody positivity for distinct Helicobacter pylori antigens in benign and malignant gastroduodenal disease. Int J Med Microbiol 2006; 296(4–5): 223–8.
Janulaityte-Günther D, Kupcinskas L, Pavilonis A, Valuckas K, Wadström T, Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol Med Microbiol 2007; 50(2): 220–5.
Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996; 91(9): 1785–8.
Lamarque D, Gilbert T, Roudot-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11(7): 721–6.
Aucher P, Petit ML, Mannant PR, Pezennec L, Babin P, Fauchere JL. Use of immunoblot assay to define serum antibody patterns associated with Helicobacter pylori infection and with H. pylori-related ulcers. J Clin Microbiol 1998; 36(4): 931–6.
Vorobjova T, Ananieva O, Maaroos H, Sipponen P, Villako K, Utt M, et al. Seropositivity to Helicobacter pylori heat shock protein 60 is strongly associated with intensity of chronic inflammation, particularly in antrum mucosa: an extension of an 18-year follow-up study of chronic gastritis in Saaremaa, Estonia. FEMS Immunol Med Microbiol 2001; 30(2): 143–9.
Barton SG, Winrow VR, Rampton DS, Crabtree JE, Beales IL, Calam J. Circulating antibodies to the 60-kD heat shock protein (hsp) family in patients with Helicobacter pylori infection. Clin Exp Immunol 1998; 112(3): 490–4.
Güdücüoğlu H, Berktaş M, Bozkurt H, Toka Ozer T, Bulut G, Oztürk O, et al. Evaluation of Western Blot method for the detection of antibodies to Helicobacter pylori antigens in patients with gastric carcinoma and cases with epigastric complaints. Microbiol Bull 2010; 44(1): 21–8.
Iaquinto G, Todisco A, Giardullo N, D'Onofrio V, Pasquale L, De Luca A, et al. Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis 2000; 32(5): 378–83.
Hassan TMM, Al-Najjar SI, Al-Zahrani IH, Alanazi FIB, Alotibi MG. Helicobacter pylori chronic gastritis updated Sydney grading in relation to endoscopic findings and H. pylori IgG antibody: diagnostic methods. J Micros Ultrastruct 2016; 4(4): 167–74.
Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol 2015; 50(6): 657–67.
Andersen LP, Gaarslev K. IgG subclass antibodies against Helicobacter pylori heat-stable antigens in normal persons and in dyspeptic patients. APMIS 1992; 100(8): 747–51.
Piñeros DM, Riveros SC, Marin JD, Ricardo O, Díaz OO. Helicobacter pylori in gastric cancer and peptic ulcer disease in a Colombian population. Strain heterogeneity and antibody profiles. Helicobacter 2001; 6(3): 199–206.
Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfert-heiner P. Anti-CagA and anti-VacA antibodies in Helicobacter pylori-infected patients with and without peptic ulcer disease in Serbia and Montenegro. Scand J Gastroenterol 2004; 39(3): 222–6.